Scalable production of branched-chain fatty acids for prenatal dietary supplements

Overview

This solution addresses a critical gap in prenatal and postnatal nutrition by enabling scalable production of isomerically-pure branched-chain fatty acids (BCFAs) for use as dietary supplements. BCFAs are naturally found in breast milk and are essential for healthy gut microbiome development in newborns. Insufficient BCFA intake in premature infants has been linked to an increased risk of necrotizing enterocolitis. Low BCFA levels have also been associated with obesity, diabetes, cancer, and brain deficiency, and certain pure derivatives have demonstrated anticancer properties.

The offering is particularly relevant to infant formula manufacturers seeking to replicate the nutritional profile of breast milk. It also serves pharmaceutical and nutraceutical companies exploring BCFA-based therapeutics and functional food developers targeting metabolic and gut health applications.

Technical specifications

Key features:

• Two-step, one-reactor chemical process using readily available, inexpensive commodity reagents
• Produces oligomeric series of BCFAs with control over chain length (n value) and end-group functionality
• Achieves a Poisson distribution of n values with a mean of 14 to 16 for even-carbon-numbered series
• Enables production of pure BCFA derivatives with chain lengths not accessible from natural sources
• Builds on validated living polymerization processes previously scaled to over 100 kilograms for polyolefin production
• Projected cost of goods of $0.30 per gram with a 40% return on investment, compared to $4,500 per gram for current synthetic BCFAs

The process leverages proprietary transition-metal catalyst and co-catalyst systems covered by University of Maryland patents. Ongoing fractionation development aims to isolate individual BCFA derivatives with specific n values from the initial product distribution.

Technology readiness level

The technology has been validated at the laboratory scale, with demonstrated production of BCFAs in quantities exceeding 10 grams. The underlying polymerization processes have previously been validated at the pilot plant level at scales exceeding 100 kilograms for polyolefin production. Current research is focused on demonstrating efficient fractionation to obtain pure individual BCFA derivatives and translating the BCFA process from bench scale to pilot plant for 100-kilogram production. Preliminary in vitro evaluations are planned to compare BCFA product performance with prior published results.